Pfizer (PFE) Free Cash Flow Growth (5y) (2014 - 2026)
Pfizer (PFE) Free Cash Flow Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -11.37% |
| Sep 28, 2025 | -4.17% |
| Jun 29, 2025 | -18.07% |
| Mar 30, 2025 | 0.75% |
| Sep 29, 2024 | 0.43% |
| Jun 30, 2024 | -25.67% |
| Mar 31, 2024 | -20.79% |
| Dec 31, 2023 | 28.30% |
| Oct 1, 2023 | -10.90% |
| Jul 2, 2023 | -21.24% |
| Apr 2, 2023 | -46.05% |
| Oct 2, 2022 | 32.97% |
| Jul 3, 2022 | 21.59% |
| Apr 3, 2022 | 36.91% |
| Oct 3, 2021 | 42.49% |
| Jul 4, 2021 | 27.41% |
| Apr 4, 2021 | 21.46% |
| Sep 27, 2020 | 0.91% |
| Jun 28, 2020 | 1.24% |
| Mar 29, 2020 | 31.07% |